TrialThe Lancet. Oncology2016

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Luca Incrocci et al.PubMed ↗Publisher ↗

No numbers read from the abstract.